Clinical Trial Update: Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

View source ↗

Summary

A completed study evaluated intravenous paricalcitol (Zemplar) for its effect on cardiac morbidity in patients with chronic kidney disease stage 5 and secondary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (paricalcitol) (paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease Stage V | Status: COMPLETED | Results posted: 2014-07-10